Background The pressor and tachycardic effects of cigarette smoking are associated with an increase in plasma catecholamines, suggesting the dependence of these effects on adrenergic stimulation. Whether the stimulation occurs at a central or a peripheral level and whether reflex mechanisms are involved is unknown.
Methods and Results
In nine normotensive healthy subjects (age, 33 .0+3.5 years, mean±SEM), we measured blood pressure (Finapres device), heart rate (ECG), calf blood flow and vascular resistance (venous occlusion plethysmography), plasma norepinephrine and epinephrine (high-performance liquid chromatography assay), and postganglionic muscle sympathetic nerve activity (microneurography from the peroneal nerve) while subjects were smoking a filter cigarette (nicotine content, 1.1 mg) or were in control condition. Cigarette smoking (which raised plasma nicotine measured by highperformance liquid chromatography from 1.0±0.9 to 44.2±7.1 ng/mL) markedly and significantly increased mean arterial pressure (+13.2±2.3%), heart rate (+30.3±4.7%), calf vascular resistance (+ 12.1±4.9%), plasma norepinephrine (+34.8± 7.0%), and plasma epinephrine (+90.5±39.0%). In contrast, muscle sympathetic nerve activity showed a marked reduction (integrated activity -31.8±5.1%, P<.01). The reduction was inversely related to the increase in mean arterial pressure (r= -.67, P<.05), but the slope of the relation was markedly less (-54.1±7.5%, P<.05) than that obtained by intravenous infusion of phenylephrine in absence of smoking. The hemodynamic and neurohumoral changes were still visible 30 minutes after smoking and occurred again on smoking a second cigarette. Sham smoking was devoid of any hemodynamic and neurohumoral effect.
Conclusions These data support the hypothesis that in humans the sympathetic activation induced by smoking depends on an increased release and/or a reduced clearance of catecholamines at the neuroeffector junctions. Central sympathetic activity is inhibited by smoking, presumably via a baroreceptor stimulation triggered by the smoking-related pressor response. The baroreflex is impaired by smoking, however, indicating that partial inability to reflexly counteract the effect of sympathetic activation is also responsible for the pressor response. (Circulation. 1994;90:248-253.) Key Words * smoking * blood pressure * nervous system * baroreflex C igarette smoking is accompanied by a marked and prolonged increase in heart rate and blood pressure.1-5 These hemodynamic changes are markedly attenuated by a-and /3-adrenergic blockade.34'6'7 They are also associated with a marked and prolonged increase in plasma norepinephrine and epinephrine,68,9 which has prompted the hypothesis that the mechanisms responsible for the pressor and tachycardic responses have an adrenergic nature.
After the report of preliminary data from our group, 10 these subjects did not cause an increase in plasma norepinephrine,1" thus failing to reproduce the smoking-dependent adrenergic activation. The present study was planned to provide information on this issue. To this aim, we studied habitual smokers in whom smoking was accompanied by a marked increase in blood pressure, heart rate, and plasma norepinephrine. We examined the effect of smoking on both sympathetic traffic and on baroreceptor-sympathetic reflex to determine whether, in the presence of a smoking-induced adrenergic activation, central and reflex sympathetic mechanisms are involved.
Methods
We studied nine normotensive healthy subjects (eight men, one woman) whose mean age was 33.0±+ 3.5 years (mean+SEM; range, 21 to 48 years). The subjects were all habitual cigarette smokers (>10 cigarettes daily). They agreed to participate in the study after being informed of its nature and purpose. The protocol of the study (see below) was approved by the ethical committee of our institution.
Hemodynamic, Microneurographic, and Humoral Measurements Grassi et al Cigarette Smoking and Sympathetic Activity 249 the R wave of an ECG lead. Calf blood flow (mL/min per 100 g) was measured four times per minute by venous occlusion plethysmography (Hokanson, EC4),15 using a mercury-in-Silastic strain gauge applied around the calf of the leg contralateral to the leg used for microneurography (see below). The strain gauge was placed 5 to 6 cm below the fibular head, and the measurements were made at constant room temperature (23°C to 24°C), with the foot circulation excluded by a cuff positioned at the ankle and inflated at a suprasystolic pressure. Calf vascular resistance was calculated as the ratio of mean arterial pressure (diastolic blood pressure plus one third of pulse pressure) to blood flow and expressed in arbitrary units.
Multiunit Plasma norepinephrine and epinephrine were measured by high-performance liquid chromatography'9 from blood samples taken from an antecubital vein. The samples were drawn into a syringe and collected into ice-chilled tubes containing EGTA glutathione. The tubes were promptly centrifuged and stored at -70°C until assayed. The blood samples were used also to measure plasma renin activity and plasma vasopressin by radioimmunoassay. The methods used for these measurements have been described in detail in previous papers.20 -22 In eight subjects, measurements included plasma nicotine concentrations. This was done by high-performance liquid chromatography, with an instrument (Aerograph 1400) equipped with a nitrogen phosphorus detector. 23 
Protocol
All subjects were asked to abstain from smoking and coffee and alcohol consumption during the 48 hours preceding the study. The study proper was conducted in the morning, 1 to 2 hours after a light breakfast, according to the following protocol: (1) The subject was put in the supine position, and the various measuring devices plus the venous cannula were set in position. (2) After 40 minutes of rest, continuous blood pressure, heart rate, and MSNA were obtained over a 15-minute period. Calf blood flow was measured during the last 2 minutes, and venous blood was withdrawn during the last 30 seconds. ( 3) The subject was asked to smoke a cigarette of a filtered type containing 1.1 mg nicotine. Puffing habits were left uncontrolled, but the subject was required to finish the cigarette within 5 minutes. During this period, blood pressure, heart rate, and MSNA were continuously recorded; calf blood flow was measured during the last 2 minutes, and venous blood was withdrawn during the last 30 seconds. (4) Blood pressure, heart rate, and MSNA measurements were continued for 15 minutes (recovery), after which the sequence of a control, a smoking, and a recovery period was repeated according to a procedure identical to the previous one.
In five subjects, the protocol described above was performed a second time except that the cigarette was replaced with a drinking straw provided with a filter to simulate the respiratory and behavioral activity of smoking (sham smoking).
In a further experimental session on seven subjects, the effects of smoking on blood pressure, heart rate, and MSNA were compared with those induced by a 5-minute intravenous infusion of phenylephrine (1.2 gg/min per kilogram body weight) capable of producing a pressor response similar to that induced by cigarette smoking.24 Phenylephrine was infused after a 30-minute recovery from smoking and a subsequent 15-minute control period.
Data Analysis
In each subject, systolic blood pressure, diastolic blood pressure, mean blood pressure, heart rate, and microneurographic data were averaged for each minute of the recording period. These data were further averaged for the 15 minutes preceding smoking (control) and the 5 minutes of smoking. Averages were also obtained of the calf blood flows and vascular resistances before and during smoking. Data from individual subjects were averaged for the group as a whole and expressed as means±SEM. The statistical significance of the changes induced by smoking was assessed by two-way ANOVA. The paired t test with Bonferroni's correction was used to locate the difference between the smoking and presmoking values, as well as between changes induced by smoking the first and the second cigarette. The same statistical analysis was used to locate the difference between the smoking and phenylephrine data. The Spearman analysis was used to assess the correlation between the various changes induced by smoking. A value of P<.05 was taken as the level of statistical significance. 25 
Results
As shown in Fig 1, smoking the first cigarette caused an increase in systolic blood pressure, diastolic blood pressure, and heart rate. Calf blood flow was unchanged by smoking, whereas calf vascular resistance was markedly increased. These hemodynamic changes were accompanied by a marked elevation in plasma norepinephrine and epinephrine. This was paralleled by a marked MSNA reduction, which was equally apparent when calculated as units and as bursts per minute (see "Methods"). The vasopressin. This was the case also for smoking a second cigarette ( Table 1) . As shown in Table 2 , sham smoking was devoid of any significant effect on ventilation rate, hemodynamic variables, MSNA, and humoral variables. Smoking the first or the second cigarette strikingly increased the plasma nicotine levels in contrast with the absence of any increase during sham smoking (Tables 1 and 2) . Fig 5 compares the effects on blood pressure, heart rate, and MSNA of cigarette smoking and phenylephrine infusion. As expected, phenylephrine infusion increased blood pressure and decreased heart rate and MSNA, both when expressed in units and in number of bursts per minute. Although they caused similar blood pressure increases, phenylephrine caused a reduction in heart rate while smoking caused an increase. Furthermore, the reduction in MSNA associated with phenyl- pressure, heart rate, and calf vascular resistance. These responses were associated with an increase in plasma norepinephrine and epinephrine, confirming previous observations.6'8'9 There was, however, no increase in postganglionic muscle sympathetic nerve traffic, which, on the contrary, showed an immediate, marked, and sustained reduction specular to the blood pressure change. This suggests that the adrenergic activation associated with smoking does not have a central origin, nor does it depend on stimulation of ganglionic sympathetic transmission. It suggests rather that smoking acts at peripheral sympathetic sites to (1) enhance catecholamine release from chromaffin tissues and/or (2) reduce the reuptake and the overall clearance of these substances.
The mechanisms involved in the central sympathoinhibition of smoking are not explained by our data. Studies in animals have reported that local injection of nicotine in several brain-stem sites is accompanied by hypotension and bradycardia,2627 suggesting that the main product of smoking may inhibit centrally sympathetic activity. In other studies, however, microinjection of nicotine in a number of other brain-stem areas has produced pressor rather than depressor effects.28,29 Furthermore, in our patients the degree of sympathetic inhibition induced by smoking showed an inverse relation with the magnitude of the pressor and vasoconstrictor responses. This suggests that, rather than being directly due to smoking (either via nicotine or via other smoking constituents), this inhibition is mediated by a baroreflex mechanism; ie, it is due to the baroreceptor stimulation brought about by the smoking-dependent peripheral adrenergic stimulation and blood pressure rise.
In the above context, however, our study provides additional new information. The slope of the sympathetic inhibition was markedly less for the pressor effect of smoking than for the pressor effect of phenylephrine, indicating a smoking-associated impairment of the baroreflex. Because smoking is accompanied by a reduction in arterial compliance,30 we can speculate that this impairment is due to a reduction in the sensitivity of stretch "sensors" such as the baroreceptors. We can speculate also that a nicotine-dependent stimulation of arterial chemoreceptors31 impairs the baroreflex.32 Finally, a third possibility is an influence of nicotine (or other component of smoking) on the integrating baroreflex centers, although this would imply a central as well as a peripheral action of smoking. Regardless of the mechanisms, however, it is clear from our data that there are probably two reasons for the sympathoexcitatory effects of smoking in humans, ie, (1) a peripheral adrenergic stimulation and (2) a partial loss of the baroreflex ability to counteract it.
Other aspects of our study deserve to be mentioned. First, in our subjects the hemodynamic, humoral, and nerve activity changes associated with smoking were still partly evident 30 minutes after the first smoking episode was completed. This provides further evidence Table 1 ). Finally, microneurography is the only technique that allows the effect of smoking on sympathetic nerve activity to be monitored directly and dynamically. However, this technique does not allow the examination of sympathetic neural activity to extend to splanchnic, renal, and other important vascular districts. Thus, whether smoking affects sympathetic activity in these districts as it does in skeletal muscle (ie, whether its sympathetic modulation is homogeneous or heterogeneous) remains to be clarified.
